RecruitingNCT06182657
The Prognostic Value of the Degree of Pathological Response of Induction Chemotherapy for NPC
The Prognostic Value of the Degree of Pathological Response at One Cycle of Induction Chemotherapy for Locally Advanced Nasopharyngeal Carcinon-a Prospective Observational Study
Sponsor
Jiangxi Provincial Cancer Hospital
Enrollment
300 participants
Start Date
Jan 1, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
This study aims to explore the prognostic value of pathological remission after one cycle of induction chemotherapy in locally advanced nasopharyngeal carcinoma, and the change of immune micro-environment after one cycle induction chemotherapy, including the density of immune cells infiltration and tertiary lymphoid structures.
Eligibility
Min Age: 18 Years
Inclusion Criteria6
- Ability to sign informed consent
- Age \> 18 years at time of study entry
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (amend based on specific study)
- Histological confirmation of NPC (regardless if EBER positive or negative)
- Locally advanced NPC, UICC stage III-IVa
- Subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.
Exclusion Criteria7
- Concurrent enrolment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study
- Distant metastases
- Prior systemic anti-cancer therapy (chemotherapy, immunotherapy, endocrine therapy, targeted therapy, radiotherapy, biologic therapy, tumour embolization, monoclonal antibodies) of the locally advanced NPC.
- History of another primary malignancy
- Female patients who are pregnant
- Known allergy or hypersensitivity to any drugs
- Judgment by the investigator that the patient is unsuitable to participate in the study and the patient is unlikely to comply with study procedures, restrictions and requirements.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06182657
Related Trials
IC Plus Low-dose Radiation Plus Cadonilimab in LANPC
NCT059417413 locations
Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
NCT0623972726 locations
Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.
NCT060592611 location
Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)
NCT065925991 location
Will a Pre-therapy Exercise Intervention Improve the Outcomes of Patients With Advanced Oesophageal Cancer?
NCT073754201 location